Esperion Therapeutics, Inc.

Esperion is a pharmaceutical company that specializes in developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The Company has two late-stage therapies in development; both with confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans. Bempedoic acid and the Company’s lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies.

Bank Name Esperion Therapeutics, Inc.
Stock Exchange NASDAQ
Symbol ESPR
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
CEO Mr. Timothy M. Mayleben M.B.A.
Employees 57
Registered Year 2008